Correspondence to editorial on "Protein-centric omics analysis reveals circulating complements linked to non-viral liver diseases as potential therapeutic targets".
作者信息
Shi Yingzhou, Yuan Guandou, Fan Xiude, Xu Chao
机构信息
Department of Endocrinology, Shandong Provincial Hospital, Shandong University, Jinan, Shandong, China.
Department of Endocrinology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
出版信息
Clin Mol Hepatol. 2024 Oct;30(4):987-988. doi: 10.3350/cmh.2024.0266. Epub 2024 Apr 19.
Abstract
摘要
相似文献
1
Correspondence to editorial on "Protein-centric omics analysis reveals circulating complements linked to non-viral liver diseases as potential therapeutic targets".致关于“以蛋白质为中心的组学分析揭示与非病毒性肝病相关的循环补体作为潜在治疗靶点”的社论的信函。
Clin Mol Hepatol. 2024 Oct;30(4):987-988. doi: 10.3350/cmh.2024.0266. Epub 2024 Apr 19.
2
Reply to correspondence on "Protein-centric omics analysis reveals circulating complements linked to non-viral liver diseases as potential therapeutic targets".对关于“以蛋白质为中心的组学分析揭示与非病毒性肝病相关的循环补体作为潜在治疗靶点”的通信的回复
Clin Mol Hepatol. 2024 Oct;30(4):1037-1038. doi: 10.3350/cmh.2024.0320. Epub 2024 May 2.
3
Protein-centric omics analysis reveals circulating complements linked to non-viral liver diseases as potential therapeutic targets.以蛋白质为中心的组学分析揭示了与非病毒性肝病相关的循环补体作为潜在的治疗靶点。
Clin Mol Hepatol. 2024 Jan;30(1):80-97. doi: 10.3350/cmh.2023.0343. Epub 2023 Dec 7.
4
Drug repositioning or target repositioning: A structural perspective of drug-target-indication relationship for available repurposed drugs.药物重新定位或靶点重新定位：现有重新利用药物的药物-靶点-适应症关系的结构视角
Comput Struct Biotechnol J. 2020 Apr 13;18:1043-1055. doi: 10.1016/j.csbj.2020.04.004. eCollection 2020.
5
Drug Repositioning for Alzheimer's Disease Based on Systematic 'omics' Data Mining.基于系统“组学”数据挖掘的阿尔茨海默病药物重新定位
PLoS One. 2016 Dec 22;11(12):e0168812. doi: 10.1371/journal.pone.0168812. eCollection 2016.
6
Integrating plasma protein-centric multi-omics to identify potential therapeutic targets for pancreatic cancer.整合血浆蛋白组学多组学分析以鉴定胰腺癌的潜在治疗靶点。
J Transl Med. 2024 Jun 10;22(1):557. doi: 10.1186/s12967-024-05363-9.
7
Multi-Omics Analysis Identified Drug Repurposing Targets for Chronic Obstructive Pulmonary Disease.多组学分析鉴定慢性阻塞性肺疾病的药物再利用靶点。
Int J Mol Sci. 2024 Oct 16;25(20):11106. doi: 10.3390/ijms252011106.
8
Gene-centric multi-omics integration with convolutional encoders for cancer drug response prediction.基于卷积编码器的基因中心多组学整合用于癌症药物反应预测。
Comput Biol Med. 2022 Dec;151(Pt A):106192. doi: 10.1016/j.compbiomed.2022.106192. Epub 2022 Oct 17.
9
Drug repositioning for diabetes based on 'omics' data mining.基于“组学”数据挖掘的糖尿病药物重新定位
PLoS One. 2015 May 6;10(5):e0126082. doi: 10.1371/journal.pone.0126082. eCollection 2015.
10
Protein-centric omics integration analysis identifies candidate plasma proteins for multiple autoimmune diseases.基于蛋白质组学的组学整合分析鉴定多种自身免疫性疾病的候选血浆蛋白。
Hum Genet. 2024 Oct;143(9-10):1035-1048. doi: 10.1007/s00439-023-02627-0. Epub 2023 Dec 24.
引用本文的文献
1
Reply to correspondence on "Protein-centric omics analysis reveals circulating complements linked to non-viral liver diseases as potential therapeutic targets".对关于“以蛋白质为中心的组学分析揭示与非病毒性肝病相关的循环补体作为潜在治疗靶点”的通信的回复
Clin Mol Hepatol. 2024 Oct;30(4):1037-1038. doi: 10.3350/cmh.2024.0320. Epub 2024 May 2.
本文引用的文献
1
Starting the journey: Understanding the roles of complement proteins in liver diseases through mendelian randomization.开启征程：通过孟德尔随机化理解补体蛋白在肝脏疾病中的作用
Clin Mol Hepatol. 2024 Apr;30(2):150-153. doi: 10.3350/cmh.2024.0116. Epub 2024 Feb 22.
2
Protein-centric omics analysis reveals circulating complements linked to non-viral liver diseases as potential therapeutic targets.以蛋白质为中心的组学分析揭示了与非病毒性肝病相关的循环补体作为潜在的治疗靶点。
Clin Mol Hepatol. 2024 Jan;30(1):80-97. doi: 10.3350/cmh.2023.0343. Epub 2023 Dec 7.
3
From complement to complosome in non-alcoholic fatty liver disease: When location matters.从非酒精性脂肪性肝病的补体到 complosome：当位置重要时。
Liver Int. 2024 Feb;44(2):316-329. doi: 10.1111/liv.15796. Epub 2023 Nov 27.
4
Editorial: New insights into the role of complement system in liver diseases.社论：对补体系统在肝脏疾病中作用的新见解
Front Immunol. 2023 Sep 8;14:1284944. doi: 10.3389/fimmu.2023.1284944. eCollection 2023.
5
Dysregulated biomarkers of innate and adaptive immunity predict infections and disease progression in cirrhosis.先天性和适应性免疫的生物标志物失调可预测肝硬化中的感染和疾病进展。
JHEP Rep. 2023 Feb 24;5(5):100712. doi: 10.1016/j.jhepr.2023.100712. eCollection 2023 May.
6
Global burden of liver disease: 2023 update.全球肝病负担：2023 年更新。
J Hepatol. 2023 Aug;79(2):516-537. doi: 10.1016/j.jhep.2023.03.017. Epub 2023 Mar 27.
7
Global epidemiology of cirrhosis - aetiology, trends and predictions.全球肝硬化的流行病学：病因、趋势和预测。
Nat Rev Gastroenterol Hepatol. 2023 Jun;20(6):388-398. doi: 10.1038/s41575-023-00759-2. Epub 2023 Mar 28.
8
Epidemiology of chronic liver diseases in the USA in the past three decades.美国过去三十年慢性肝脏疾病的流行病学。
Gut. 2020 Mar;69(3):564-568. doi: 10.1136/gutjnl-2019-318813. Epub 2019 Jul 31.
Zotero 插件